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The use of mesh grafts for the adjunctive therapy of pelvic
organ prolapse and stress incontinence has become com-
monplace among those surgeons treating these conditions.
This change from the exclusive use of native tissue for
prolapse repair utilizing sutures to the current use of mesh
in many such surgeries, including primary surgeries even
with prolapse not to the hymenal ring and asymptomatic as
far as the patient is concerned, has occurred by and large
with little evidence-based medicine. Graft usage continues
despite recommendations from international societies and
other authorities that there is no evidence to suggest mesh
should be used in all prolapse surgeries [1, 2]a n d
particularly primary surgeries. Unfortunately, disastrous
results which are not treatable by any means are sometimes
seen. Recent studies report an 88% and 81% anatomical
cure rate for cystocele repair without mesh [3, 4] and the
literature shows anatomical cure rates from 37% to 100%
[5]. When standard surgery has been compared to surgery
utilizing mesh, either non-statistically significant differ-
ences are found [6] or a significant difference for
anatomical correction, but a non-significant difference in
the quality of life questionnaire results [7]. A Cochrane
Review in 2007 found no level I evidence to support the
use of mesh for the repair of any vaginal compartment [8].
Polypropylene meshes differ in the way the fibers are
arranged in the mesh. Typically they are described as
macroporous or microporous depending on the size of the
pores going through the mesh. Meshes may be braided or
woven or monofilament or multifilament. Figure 1 shows
the basic construct of a macroporous mesh. Note the large
pores, but also the interstices located between the polypro-
pylene fibers which are typically <10 μm. Amid 1997
meshes were classified into the following types: type I,
totally macroporous with pores of >75 μm; type II, totally
microporous with pores≤10 μm; type III, microporous with
macroporous components; and type IV, non-porous [9].
Two types of microporous meshes are shown in Figs. 2
and 3.
Manufacturing companies have brought new techniques
and grafts to physicians and hospitals for sale through the
food and drug administration's (FDA) 510(k) process of
clearance of devices. In a previous publication, I mistakenly
indicated that the FDA approved devices by this process
when the proper term is “clearance” [10]. Yet, when I asked
the representatives of all the companies present at the
American Urogynecology Society's annual meeting in
2006, all responded that their product was approved by
the FDA. Only one company supervisor acknowledged the
clearance process. Physicians have been misled into
thinking that these new techniques and grafts have been
studied in sufficient patients to realistically determine
efficacy and adverse events and that both technique and
device are approved by the FDA. The FDA does not
approve or clear surgical procedures, only the devices
which are used to accomplish the surgery which would
include the mesh and the trocars.
The 510(k) process requires manufacturing companies to
provide information to the FDA for its evaluation of the
proposed product. These include many characteristics of the
new graft in the categories of biocompatibility and product
characterization [11]. The former requires acute implantation
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DOI 10.1007/s00192-010-1227-9studies of 12 weeks, including histology of the surrounding
tissues and if the device is to remain in the body longer than
30 days then chronic studies are needed. The latter asks for
information about the product structure which is considered
critical in determining the equivalence of a proposed device.
Such information would include data on the thickness, density,
stiffness, and weave characteristics along with pore size, tensile
strength, suture pullout strength, burst strength, and tear
resistance. The implanted surface area is not yet a requirement.
The manufacturer must determine which previously
FDA 510(k)-cleared device is similar enough with the
characteristics noted above in order to establish a predicate
that the FDA could agree to label the new device as a
substantially equivalent device. In order to be labeled by
the FDA as substantially equivalent, the device must have a
similar indication statement, the same indications for use
and the same technological characteristics. Several recent
companies have claimed substantial equivalence to the
TVT® mesh manufactured by Ethicon, Inc. These are the
IVS Tunneller® sub-urethral sling mesh manufactured by
Tyco, Inc. and the ObTape® mesh for transobturator sub-
urethral sling use, manufactured by Mentor, Inc. The TVT®
monofilament mesh is seen under magnified view in Fig. 1.
The IVS® multifilamentous mesh is shown in Fig. 2 and
the ObTape® multifilamentous mesh in Fig. 3. All of these
meshes are manufactured from polypropylene. The TVT®
mesh is monofilament with very large pores and a limited
amount of interstices. The IVS® constitutes a woven
polypropylene mesh combining macroporous and micropo-
rous characteristics. The ObTape® is a thermally bonded
polypropylene microporous mesh. It is said to combine this
with macroporous characteristics with a 50-μm pore size
often quoted. However, as seen in Fig. 3 there are no true
pores, only passages likened to cul-de-sacs.
The companies manufacturing the IVS® and ObTape®
grafts have chosen the TVT® mesh as their respective
predicates, which are supposed to have the same technological
Fig. 2 A type 3 mesh consisting of large pores and surrounding
bundles of polypropylene fibrils (IVS Tunneller® mesh). The surface
area is considerably increased compared to the macroporous mesh
shown in Fig. 1 which enhances the area for bacterial contamination
by providing many entry points and increasing the surface area while
promoting wicking of bacteria and fluids into and through the mesh.
Used with the kind permission from Springer Science and Business
Media: Slack M, Sandhu JS, Staskin D, Grant RC. In vivo comparison
of suburethral sling materials. Int Urogynecol J 2006; 17:106–10,
Fig. 2. © 2006 International Urogynecology Journal
Fig. 3 A totally microporous mesh (ObTape®). Note the diamond
shaped area of heat welding. The polypropylene fibrils are flattened and
do not exhibit actual pores. At the arrow is a blind pouch where more
fibrils are seen behind the end of the pouch. These blind pouches
prevent full incorporation of the mesh into the tissue and discourage
neovascularization. Used with the kind permission from Springer
Science and Business Media: Slack M, Sandhu JS, Staskin D, Grant
RC. In vivo comparison of suburethral sling materials. Int Urogynecol J




Fig. 1 A typical macroporous mesh construct (TVT mesh). Filaments
can be mono- or macro-filamentous. Note the large pores. The
interstices are considerably smaller and make it difficult for host
defenses to reach bacterial contamination located there and for fibrous
tissue to fully incorporate the mesh into the host tissue. Used with the
kind permission from Springer Science and Business Media: Deprest
J, Zheng F, Konstantinovic M, Spelzini F, Claerhout F, Steensma A,
Ozog Y, De Ridder D. The biology behind fascial defects and the use
of implants in pelvic organ prolapse repair. Int Urogynecol J 2006;17:
S16–25, Fig. 4. © 2006 International Urogynecology Journal
1182 Int Urogynecol J (2010) 21:1181–1183characteristics as the predicate. A simple visual comparison of
the constructs of the IVS® (Fig. 2) and ObTape® (Fig. 3)
meshes with the TVT® mesh in Fig. 1 indicates that these
requirements do not seem to have been met. Interestingly
enough the TVT® mesh chose as its predicate the Protegen
Sling® (Boston Scientific, Natick, MA) device which was
subsequently declared by the FDA to be mislabeled and
adulterated with a statement of concurrence with its recall.
For whatever reason, the FDA did not realize the
differences in the technological characteristics between the
devices when it provided clearance for marketing. Perhaps
increased funding to the FDA or a modification of the 510
(k) process would allow the FDA to increase its vigilance
before clearing devices for market.
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